Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Prescribing telehealth peptides is legal when the product has a lawful source, the clinician is licensed where the patient is located, the remote evaluation meets the standard of care, and a pharmacy licensed in that state can ship it. Here is how each rule works, plus controlled substances and shipping.
Prescribing telehealth peptides is legal when four things hold: the product is an FDA-approved drug or is compounded by a licensed pharmacy from a bulk substance federal law allows, the clinician is licensed in the state where the patient is located during the visit, the remote evaluation meets the same standard of care as an in-person one, and a pharmacy licensed in the patient's state can dispense and ship it. Most peptides are not controlled substances, so the federal in-person exam requirement for controlled drugs does not apply to them, though it does apply to testosterone and other anabolic steroids that peptide programs often prescribe alongside them.
A large share of peptide practice now runs by video visit, and most of the problems it creates come from one of those gates. This guide takes them in order, then covers controlled substances, shipping compounded products across state lines, and what the chart should show.
Status as of October 29, 2026. This guide covers federal law and the rules most states share. Telehealth, scope of practice, and pharmacy licensing differ by state; our guide to who can prescribe peptides has license-by-license detail.
| Gate | The rule | Where it comes from |
|---|---|---|
| Product | An FDA-approved drug, or a compounded peptide made from a bulk substance eligible under section 503A or 503B | The FD&C Act and FDA's bulk substance lists |
| License | You hold an active license in the state where the patient is located during the visit | State medical, nursing, and PA practice acts |
| Relationship and exam | The remote evaluation establishes a valid clinician-patient relationship and meets the in-person standard of care | State telehealth statutes and board rules |
| Controlled substances | An in-person evaluation is required before prescribing a scheduled drug, unless a telemedicine exception or DEA flexibility applies | The Ryan Haight Act and DEA rules |
| Pharmacy | The dispensing pharmacy is licensed in the patient's state, including any nonresident sterile compounding license for injectables | State pharmacy law |
A prescription that clears every other gate can still fail at the pharmacy, which is the one most new telehealth practices underestimate. Which peptides qualify for compounding is changing during 2026; our map of the FDA compounding categories tracks the current status. Individual states can add gates of their own, such as in-person rules for particular drug classes.
States regulate the practice of medicine where the patient is, so a clinician treating a patient located in another state generally needs a license in that state, or a telehealth registration where the state offers one. A patient who usually lives in Florida but logs on from a vacation rental in Georgia is a Georgia patient for that visit. Record the patient's location at the start of every encounter.
Compacts reduce the paperwork without removing the requirement.
| Compact | Who it covers | What it does in 2026 |
|---|---|---|
| Interstate Medical Licensure Compact | Physicians | Expedites a full license in each member state. 44 states plus DC and Guam have joined, a few of them still implementing. Each state still issues its own license. |
| Nurse Licensure Compact | RNs and LPNs | One multistate license to practice as a nurse in member states. It does not carry APRN prescriptive authority. |
| APRN Compact | Nurse practitioners and other APRNs | Not in effect. It activates once seven states enact it, and fewer have. |
| PA Licensure Compact | Physician assistants | Enacted in 30 states. Privileges to practice are not available yet; the compact commission expects them in early to mid 2027. |
For now, an NP or PA prescribing across state lines needs a license in each state, plus whatever collaboration or practice agreement that state requires. A collaborating physician licensed only in your home state does not satisfy a reduced-practice state's rules for its own patients. Our guides for nurse practitioners and physician assistants cover the agreements.
States require a legitimate clinician-patient relationship before a prescription, and most let telehealth establish one, under conditions that vary by state and drug class. Two examples show the range. California makes it unprofessional conduct to prescribe "without an appropriate prior examination and a medical indication," allows the exam by telehealth if it meets the standard of care, and requires documented telehealth consent before care starts. Texas allows prescribing after a telemedicine evaluation with no prior in-person visit, held to the same standard as an in-person encounter, and bars a pharmacist from dispensing a prescription the pharmacist knows or should know was issued without a valid relationship, treating a telemedicine relationship that meets its statute as valid. Our California and Texas guides cite the statutes.
The standard of care is the test, and a medical board will read the chart with that test in mind. A questionnaire reviewed asynchronously, with no history beyond a checkbox list and no labs, is the pattern that draws complaints. A defensible peptide evaluation by video looks like an in-person one minus the hands-on exam: the complaint and the goal, a full history including cancer history, current medications and prior peptide use with its source, baseline labs, and a written plan.
The practice protocol should settle four clinical questions before the first patient books:
| Question | What a working protocol answers |
|---|---|
| Examination | Which findings the visit can assess by video, and which presentations need an in-person exam first |
| Labs | How baseline and monitoring labs are drawn, usually through a national lab network's local draw sites |
| Injection teaching | How technique is demonstrated and verified remotely, with a teach-back on camera |
| Escalation | Where a patient goes for an in-person assessment when an adverse effect needs one |
The Ryan Haight Online Pharmacy Consumer Protection Act, at 21 U.S.C. 829(e), bars dispensing a controlled substance by means of the internet without a valid prescription, and a valid prescription generally requires at least one in-person medical evaluation. The statute has telemedicine exceptions, and since 2020 the DEA has suspended the in-person requirement through temporary rules. The fourth extension runs through December 31, 2026, and the DEA's permanent special registration rule for telemedicine has been under White House review since August 25, 2026 and had not been published when this guide was updated.
The act reaches only scheduled drugs. Most peptides used in practice, including growth hormone secretagogues and compounded repair peptides, are not on the federal schedules. Three neighbors are:
Testosterone and other anabolic steroids are Schedule III under 21 CFR 1308.13. A program that starts a patient on peptides by video and adds testosterone is prescribing a controlled substance, and the rules above apply to that prescription.
Human growth hormone is not federally scheduled, but distributing it outside an authorized indication is a federal crime under 21 U.S.C. 333(e). Anti-aging and performance use in a healthy adult fall outside those indications. Some states, Texas among them, also schedule it under state law.
State schedules can add drugs the federal list omits. Check the patient's state before assuming a peptide is unscheduled.
If the DEA flexibilities lapse on January 1, 2027 without a permanent rule, patients receiving a controlled substance after video-only evaluation will need an in-person evaluation or a qualifying exception. Identify those patients now.
A telehealth prescription is only as good as the pharmacy's ability to ship it. A 503A pharmacy compounds for an identified patient on a prescription and ships to that patient, so it needs a license in the patient's state. Many states also require a separate nonresident license for sterile compounding, which covers every injectable peptide. California requires an out-of-state pharmacy to hold a California nonresident sterile compounding license and pass inspection before it ships injectables in, and Texas requires a Class E-S license. Fewer pharmacies hold those, which is why California patients are often the hardest to fill for.
The workaround some practices use, shipping to an office in a state the pharmacy serves and re-shipping on dry ice, adds days, cost, and a handling step the practice now owns. Check that state's pharmacy law before relying on it, because forwarding a dispensed drug can itself require a license.
Telehealth also changes the office stock question. A practice with no exam room has nowhere to administer 503B office stock, so nearly all telehealth peptide prescriptions are patient-specific 503A fills shipped to the patient's home. Our guide to 503A vs. 503B pharmacies explains the difference, and the compounding pharmacy guide covers how to verify a pharmacy's licenses.
Formulation matters for shipping too. Ready-to-inject liquid preparations have to travel overnight on ice or dry ice, which in Dr. Morse's practice adds $50 to $70 to a vial costing $100 to $150, and a box that sits in a carrier warehouse over a weekend arrives warm. Avoid shipping liquid product on a Thursday or Friday unless overnight delivery is confirmed. Lyophilized powder ships without a cold chain and is reconstituted at home, which moves the risk to the patient's technique, so the remote teaching in the protocol carries more weight. Our guide to storing and handling compounded peptides covers receipt, refrigeration, and what patients need to know before a vial goes home.
Search for telehealth peptides and the first page is clinics selling peptide therapy straight to patients, which is also the format regulators watch. Telehealth companies have drawn their attention. In 2025 and 2026 FDA sent dozens of warning letters to telehealth firms over marketing of compounded GLP-1 drugs, citing claims that implied compounded products were equivalent to approved drugs or were made by the telehealth brand itself. A practice advertising peptides online answers to the same misbranding rules, to the Federal Trade Commission's requirement that health claims be substantiated, and to the advertising rules of every state board where it holds a license. A peptide menu with prices and benefit claims, aimed at consumers, is the format that attracts the most scrutiny.
Confirm in writing that your malpractice policy covers telehealth visits, covers patients located in each state where you are licensed, and covers peptide therapy specifically. Some policies exclude one of the three, and a policy written for an in-person practice in one state often excludes all three. Add the coverage or change carriers before the first out-of-state patient.
| Record | What it should show |
|---|---|
| Location and license | The patient's location at the visit and your license number in that state |
| Consent | Telehealth consent, plus the product disclosure for a compounded or off-label prescription |
| Evaluation | History, goal, contraindications, prior peptide use and its source, and baseline labs |
| Prescription | Product, dose in units, route, site, frequency, duration, and refills |
| Pharmacy | The dispensing pharmacy, its license in the patient's state, and the shipping method |
| Teaching and follow-up | The injection teach-back, the follow-up interval, and the escalation plan |
Our peptide therapy consent kit includes the compounded product disclosure, and our guide to adding peptide therapy to your practice covers the rest of the setup.
Peptavo's peptide course for physicians includes a module on telemedicine and multi-state practice, along with sourcing, documentation, injection teaching, and the protocols themselves, and is designated for up to 20 AMA PRA Category 1 Credits™. NPs and PAs can take the same course through the nurse practitioner and physician assistant pages.
Yes, when the clinician is licensed in the patient's state, the remote evaluation meets the standard of care, and the product has a lawful source: an FDA-approved drug, or a peptide compounded by a licensed pharmacy from an eligible bulk substance. Research use only products are neither approved nor lawfully compounded, so they cannot be prescribed to patients by telehealth or in person.
Yes. Licensure follows the patient's location during the visit, not the clinician's. The Interstate Medical Licensure Compact speeds up physician licenses in member states, but each state still issues its own.
Only to peptides that are controlled substances, and most are not. It does apply to testosterone and other anabolic steroids, which are Schedule III, and the DEA's temporary telemedicine flexibilities for those run through December 31, 2026.
Only with a license in each patient's state and any collaboration agreement that state requires. The APRN Compact, which would allow multistate practice, is not yet in effect.
No. A pharmacy can ship only to states where it holds a license, and many states require a separate nonresident sterile compounding license for injectables. California is among the most demanding, so confirm the pharmacy ships to the patient's state before promising a protocol.
If they lapse without a permanent rule, prescribing a controlled substance by telemedicine will again require an in-person evaluation or a statutory exception. Peptides that are not scheduled are unaffected, but testosterone prescribed by video visit would be.
